Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
22 23 Next >
News headline image
2 Short-Squeeze Candidates That Could Go Parabolic ↗
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
News headline image
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application ↗
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
News headline image
The Latest Analyst Ratings for bluebird bio ↗
 
Via Benzinga
News headline image
Caterpillar To Rally Over 37%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the stock with an Overweight rating. Pure Storage shares fell 2.1% to... 
Via Benzinga
News headline image
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial ↗
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
News headline image
Why Is Bluebird Bio (BLUE) Stock Up 17% Today? ↗
Bluebird Bio received a major lift from JPMorgan Chase regarding its gene-editing therapeutic, sending BLUE stock flying. 
Via InvestorPlace
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Should Investors Buy the Dip With Bluebird Bio Stock? ↗
The case for buying the dip isn't exactly a slam dunk. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023 ↗
 
Via Benzinga
News headline image
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
News headline image
1 Small-Cap Stock That Could Soar in 2023 ↗
Investors should think twice before initiating a position. 
Via The Motley Fool
News headline image
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
News headline image
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May ↗
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023 ↗
 
Via Benzinga
News headline image
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday. 
Via Benzinga
News headline image
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
From bluebird bio
Via Business Wire
News headline image
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 ↗
 
Via Benzinga
News headline image
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
News headline image
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
News headline image
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis ↗
 
Via Benzinga
News headline image
Nasdaq Surges 100 Points; US Producer Prices Drop In March ↗
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 33,650.06 while the... 
Via Benzinga
News headline image
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio ↗
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
News headline image
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.